Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review.

Abstract

AIM:

We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long-acting injectable second-generation antipsychotic (LAI-SGA) therapy due to adverse events (AEs).

METHODS:

The study included patients with schizophrenia and related psychotic disorders who commenced LAI-SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan.

RESULTS:

We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone-LAI groups, respectively, discontinued due to AEs since the start of LAI-SGA therapy. Three patients required hospitalization for AE treatment.

CONCLUSION:

The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results.

• Authors: Taro Kishi, Kenji Sakuma, Makoto Okuya, Masakazu Hatano, Nakao Iwata
• Journal: Neuropsychopharmacology reports (Neuropsychopharmacol Rep) Vol. 41 Issue 3 Pg. 422-425 (09 2021) ISSN: 2574-173X [Electronic] United States
• PMID: 34212530 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

Chemical References

• Antipsychotic Agents
• Delayed-Action Preparations
• Aripiprazole
• Paliperidone Palmitate

Topics

• Antipsychotic Agents (adverse effects)
• Aripiprazole (adverse effects)
• Delayed-Action Preparations (therapeutic use)
• Humans
• Paliperidone Palmitate (adverse effects)
• Schizophrenia (drug therapy)